Search research articles
Contact Us
Filters
Showing results (31-40 of 129) with videos related to
Page
of 13
Sort By:
The Oncologist
|
May 7, 2016
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
Khurum H Khan, Mabel Wong, Karim Rihawi, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
August 31, 2021
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF<sup>V600</sup> wild-type colorectal cancer
Alexandros Georgiou, Adam Stewart, Georgios Vlachogiannis, et al.
Journal of Proteome Research
|
August 27, 2025
Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response
Jimmy Maillard, Theodoros I Roumeliotis, Ekta Paranjape, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 20, 2006
The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer
Udai Banerji, Sue Ashley, Jim Coward, et al.
Bioanalysis
|
July 11, 2017
Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma
Monique Zangarini, Philip Berry, Julieann Sludden, et al.
BJC Reports
|
November 8, 2024
Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer models
Adam Stewart, Jiin Song, Lisa Pickard, et al.
Molecular Cancer Therapeutics
|
May 7, 2020
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer
Charlotte K Milton, Annette J Self, Paul A Clarke, et al.
Molecular Oncology
|
April 23, 2017
Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma
Elizabeth R Tucker, Jennifer R Tall, Laura S Danielson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors
Muhammad Wasif Saif, Chris Takimoto, Monica Mita, et al.
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development
Daniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 129) with videos related to
Sort By:
Page
of 13
The Oncologist
|
May 7, 2016
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
Khurum H Khan, Mabel Wong, Karim Rihawi, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
August 31, 2021
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF<sup>V600</sup> wild-type colorectal cancer
Alexandros Georgiou, Adam Stewart, Georgios Vlachogiannis, et al.
Journal of Proteome Research
|
August 27, 2025
Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response
Jimmy Maillard, Theodoros I Roumeliotis, Ekta Paranjape, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 20, 2006
The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer
Udai Banerji, Sue Ashley, Jim Coward, et al.
Bioanalysis
|
July 11, 2017
Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma
Monique Zangarini, Philip Berry, Julieann Sludden, et al.
BJC Reports
|
November 8, 2024
Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer models
Adam Stewart, Jiin Song, Lisa Pickard, et al.
Molecular Cancer Therapeutics
|
May 7, 2020
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer
Charlotte K Milton, Annette J Self, Paul A Clarke, et al.
Molecular Oncology
|
April 23, 2017
Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma
Elizabeth R Tucker, Jennifer R Tall, Laura S Danielson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors
Muhammad Wasif Saif, Chris Takimoto, Monica Mita, et al.
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development
Daniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Page
of 13